Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,923,093 papers from all fields of science
Search
Sign In
Create Free Account
Herceptin
Known as:
Herceptin®
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
erbB-2 Receptor
trastuzumab 22 MG/ML Injectable Solution [Herceptin]
Broader (1)
trastuzumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of Breast Lumps in Females with Assessment of Estrogen Receptor , Progesterone Receptor and HER 2 / NEU Status in Patients with Breast Carcinoma
Prachie Garg
,
Pamelle Yadav
2018
Corpus ID: 157060385
DOI: 10.21276/sjams.2018.6.1.69 Abstract: Breast lump is one of the most common surgical problems in females. Diagnosis of breast…
Expand
2012
2012
Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
R. Tuma
Journal of the National Cancer Institute
2012
Corpus ID: 29886075
the researchers did the opposite experiment and used trastuzumab to block HER2 activity in HER2-amplified cell lines, they saw…
Expand
2012
2012
Abstract PD02-01: Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy
J. Christiansen
,
N. Barakat
,
+8 authors
D. Slamon
2012
Corpus ID: 71339067
Introduction: There have been disparate results reported in breast cancer testing for HER2 assessment as measured by protein…
Expand
2010
2010
Enhanced targeted MRI contrast using silica coated magnetite nanoparticles
J. Lodhia
,
D. Pouniotis
,
G. Mandarano
,
P. Eu
,
S. Cowell
2010
Corpus ID: 33164795
Introduction MRI is a high spatial resolution non-invasive technique but it has low specificity for targeting explicit…
Expand
2009
2009
Combination effects of herceptin, pertuzumab and bevacizumab in a HER2-overexpressing breast cancer xenograft model.
N. Alami
,
Y. Sun
,
P. De
,
A. Benmassaoud
,
Y. Wang
,
B. Leyland-Jones
2009
Corpus ID: 72018593
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #4058 Background: The HER2 receptor is overexpressed in…
Expand
2007
2007
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
M. De Tursi
,
C. Carella
,
+5 authors
Stefano Iacobelli
2007
Corpus ID: 73739886
1060 Background: The combination of doxorubicin and herceptin (H) has been proven to be an effective regimen in metastatic breast…
Expand
2006
2006
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer
P. Khalili
,
A. Arakelian
,
G. Chen
,
G. Singh
,
S. Rabbani
Oncogene
2006
Corpus ID: 40079885
Correction to: Oncogene 2005; 24: 6657–6666. doi:10.1038/sj.onc.1208790 Published online 8 August 2005 Since publication of the…
Expand
2001
2001
Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression
Joel M. Salazar Cavazos
,
Juan Francisco González Guerrero
,
William O. Brito Villanueva
,
J. A. Mestres
,
José M. Baselga Torres
Revista de Oncología
2001
Corpus ID: 68895494
HER2 is a 185 kDa transmembrane receptor with tyrosine kinase activity encoded by the HER2/neu gene. HER2 is overexpressed in 25…
Expand
Review
2000
Review
2000
Use of an antibody to target geldanamycin.
J. Mendelsohn
Journal of the National Cancer Institute
2000
Corpus ID: 9518026
The promise of antibodies as mediators of effective targeted anticancer therapy is beginning to be fulfilled. In the past few…
Expand
2000
2000
Stellenwert von Paclitaxel in der Therapie des Mammakarzinoms
R. Kreienberg
Der Onkologe
2000
Corpus ID: 26214744
Nach den Empfehlungen, die im Rahmen der State-of-the-Art-Meetings in Gravenbruch (1998, 1999) formuliert wurden, sollten…
Expand